Exhibit 99.2



         NANOBAC LIFE SCIENCES ANNOUNCES SPACE ACT AGREEMENT WITH NASA:
                NASA's Johnson Space Center to Study Nanobacteria


TAMPA, Fla. (September 13, 2004) -- Nanobac Life Sciences, Inc. (OTCPK:NNBP) is
pleased to announce the signing of a Space Act Agreement with NASA's Johnson
Space Center (JSC), Houston Texas, to collaborate on research on Nanobacteria
and its nature and role in pathological calcification, including the detection
and treatment of the pathogen. Since Astronauts may be more prone to an
increased rate of pathological calcification while in a zero gravity
environment, the collaboration will bring a new approach to NASA's need to
better understand the effects of long-term space travel on humans. In addition,
Nanobac's work provides a model for studying mineralized organic matters that
could aid NASA in the search for extraterrestrial life.


Nanobac co-founder and Director of Science, Neva Ciftcioglu, Ph.D. will remain
at NASA JSC as Senior Scientist and principal researcher. Under the agreement,
NASA will provide workspace at JSC for Nanobac's personnel located at JSC. The
agreement further provides Nanobac the opportunity to work together with a
multidisciplinary team of NASA researchers while having access to basic
laboratory services for nanobacteria science, including electron microscopy,
molecular biology and geology-mineralogy research facilities. Projects ranging
from searching for nanobacteria biosignatures in earth fossils and in Mars
meteorites to diagnosing and treating nanobacteria infection are anticipated.
Nanobac will provide JSC with equipment and specialty supplies for nanobacteria
research and apply its pioneering diagnostic and treatment experience in the
field.

"We are pleased to be able to provide our Director of Science to NASA for these
important projects," commented John Stanton, Nanobac's President and Chief
Executive Officer. "We look forward to a very rich and rewarding research
collaboration with NASA. We appreciate the opportunity to work with some of the
country's most talented scientists."

This announcement shall not be construed to imply that NASA currently or in the
future endorses or sponsors any NANOBAC product or service.


About Nanobacteria
Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating
organism ever detected - at 50 to 500 billionths of a meter, 1/1000th the size
of the smallest previously known bacteria. Nanobacteria have been implicated in
a variety of human diseases associated with pathological calcification.

Nanobacteria were first discovered in 1988 by a Finnish researcher, and Nanobac
OY co-Founder Olavi Kajander, M.D., Ph.D. Medical microbiologist Neva
Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated work with





nanobacteria over the past 13 years has put them at the forefront of research
into this medically important pathogen. Their research established that the
blood-borne nanobacteria forms slow-growing calcified colonies in arteries and
organs.

Nanobac has identified two biomarkers of nanobacterial infection. These tests
are being developed as the NB2 test, which is composed of the nanobacteria
antigen test, and the nanobacteria IgG antibody test. The Nanobac IgG test is
designed to measure the body's immune response to the nanobacterial infection.
The Company is in the final stages of development of the nanobacteria antigen
test.

About Nanobac Lifesciences
Nanobac Life Sciences, Inc. is dedicated to improving people's health through
the detection and eradication of Nanobacterium sanguineum (nanobacteria). The
Company's pioneering research is establishing the pathogenic role of
nanobacteria in calcification, particularly in coronary artery heart disease and
vascular disease. Nanobac has identified two biomarkers of nanobacterial
infection, and expects to file for FDA approval of its NB2(TM) ELISA assay to
detect nanobacterial antigen and IgG antibody. It is also leveraging its
proprietary knowledge and intellectual property to develop the first FDA
approved therapeutic to detect and treat nanobacterial infection. The Company
currently markets, through its wholly owned subsidiary, Nanobac Sciences, a
patented nanobiotic regimen that it developed.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more
information, please visit our website at: www.nanobaclifesciences.com.
                                          ----------------------------

Investors are cautioned that certain statements contained in this document as
well as some statements in periodic press releases and some oral statements of
Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within
the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act).
Forward-Looking statements include statements which are predictive in nature,
which depend upon or refer to future events or conditions, which include words
such as "believes," "anticipates," "intends," "plans," "expects," and similar
expressions. In addition, any statements concerning future financial performance
(including future revenues, earnings or growth rates), ongoing business
strategies or prospects, and possible future Nanobac Life Sciences, Inc.
actions, which may be provided by management, are also forward-looking
statements as defined by the Act. Forward-Looking statements involve known and
unknown risks, uncertainties, and other factors which may cause the actual
results, performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by such
forward-looking statements and to vary significantly from reporting period to
reporting period. Although management believes that the assumptions will, in
fact, prove to be correct or that actual future results will not be different
from the expectations expressed in this report. These statements are not
guarantees of future performance and Nanobac Life Sciences, Inc. has no specific
intention to update these statements.